This analysis used optimisation algorithms to determine the most efficient combinations of vial sizes for four drugs for which the dosing was based on weight or BSA, by observing the impacts on average cost per dose and average number of vials required per dose when the sizes of two available products are varied simultaneously.
The costs of new medicines could be reduced, and their cost effectiveness enhanced, by planning for efficient vial sizes in the manufacturing process. This could lead to reduced wastage, lower cost of goods and ultimately improved patient access to medicines. Altering the vial sizes of drugs in this analysis is equivalent to price discounts between 2.2% and 7.6%.
Costs were higher in all cases where a larger vial was a multiple of the smaller vial, with cost savings even achievable by increasing the size of vials where the current vial sizes are divisible.
During the pharmaceutical development process, more consideration should be given to ensuring vial sizes are chosen efficiently, to minimise costs and reduce wastage. Vial sizes of pharmaceuticals for infusion -the potential for cost reductions and reduced wastage by optimising fill volumes
Drugs included in analysis
Four drugs available in two product sizes were chosen as examples: belimumab, cetuximab, panitumumab and pemetrexed. Each of these treatments is dosed based on the weight or body surface area of the patient, and has two vial sizes available that are linearly priced (both sizes have the same cost per mg). The dosing and costs of these drugs, including the sizes of the products available, were sourced from the Monthly Index of Medical Specialities (MIMS). 1
Estimation of patient characteristics
The analysis includes two drugs that are dosed based on patient weight and two that are based on patient BSA. The cost of administering these drugs to a relevant patient population was estimated using data from the Health Survey for England (HSE), from which complete information was available on weight, height and age for 5,427 individuals. 2 BSA was calculated using the Du Bois formula. 3 Data from individuals aged between 31 and 80 (inclusive) have been used for the analysis. Previous research has shown that the weight and BSA characteristics observed in this dataset represent an appropriate proxy for populations typically seen in clinical trials (paper submitted for publication).
The variation in patient weight and BSA was incorporated by fitting lognormal distributions to the individual patient data from the HSE. Both curve fitting and the analysis were performed in the statistical software R. 4 The curve parameters used are presented in Table 1 , and the distributions are displayed graphically in Figure 1 along with histograms of the individual level data.
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The results of the analysis indicated that the average cost of drug acquisition can be reduced simply by changing the size of vials. In all cases, smaller vials were associated with more efficient dosing. The savings that could be achieved for each of the drugs is shown in Table 3 .
Analysis
Hypothetical sizes of the two vials were varied simultaneously for each product, with the size of vials considered ranging from 50% to 200% of the currently available products in the UK (as identified using MIMS, presented in Table 2 ). Vial size was varied in increments of 10mg.
Across the range of vial sizes tested, the cost per vial was calculated, maintaining the linear pricing observed in the available products. Table 2 contains the cost per mg assumed for each drug, as well as the dosing information.
For each combination of vial sizes, the averages of cost per dose and number of vials required per dose was calculated. Possible vial combinations were ranked by the total amount of drug provided. Where combinations were tied on the amount of drug (and therefore cost, given linear pricing), the combinations that required the fewest number of vials were preferred. Weight and BSA thresholds were calculated for each dose, and the parametric distribution was evaluated to estimate the total number of patients for whom vial combinations would be appropriate. If the combinations of vials considered were not sufficient to provide a full dose to all patients (that is, the cumulative density of the distribution is not evaluated as one) without requiring more than 50 vials, the vial size combination was determined invalid and not included in the analysis.
Whilst smaller vials are associated with more efficient dosing, they also result in a greater number of vials used to make up the required dose. This might be associated with additional costs of preparation administration time. Although, the impact is unlikely to be large if the drug is administered intravenously (the case with all of the drugs included in this analysis) as vials will be collected in a bag for infusion, rather than given as multiple injections. There may, however, be additional costs if the number of vials is excessive and time is required for preparation. However, increased administration costs will be offset by savings from avoided wastage.
Whilst the savings achieved for a single dose may be modest, these may sum to a considerable amount over the course of treatment. All of the drugs included in this analysis are dosed continually, and the average number of doses per year and the costs and savings accrued over 1 year of treatment are shown in Table 4 .
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Joshua Figure 2 presents a heat map of the average cost per dose for pemetrexed, across the ranges of vial sizes that were tested. This demonstrates that pairs of vial sizes are more efficient when the volume of the larger vial was not a multiple of the volume of the smaller vial (the red areas indicate the highest costs when this occurs). This finding is particularly interesting given that the larger vial is a multiple of the smaller vial size for three of the four drugs selected for this analysis. This also demonstrates that, whilst smaller vials are generally associated with reduced wastage and reduced cost, savings could be made compared to the status quo even if vial sizes were increased -provided that the larger product was no longer a multiple of the smaller size.
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